Treatment for Freckles, Vitiligo, and Hyperpigmentation — Procedure Guide, Recovery & Risks | MyMedicPlus

Skin pigmentation disorders encompass a clinically important spectrum of conditions involving abnormal melanin production, abnormal melanocyte numbers, or abnormal melanocyte function. Freckles (ephelides) are UV-induced focal accumulations of melanin in the basal layer of the epidermis, appearing in fair-skinned, MC1R-variant individuals and darkening with sun exposure. Solar lentigines (age spots) are acquired benign pigmented lesions caused by localised proliferation of melanocytes with increased melanin production, most prominent on photo-exposed skin in adults over 40. Melasma is a chronic acquired disorder of hyperpigmentation predominantly affecting women, characterised by symmetric brown macules in sun-exposed areas — centrofacial, malar, and mandibular distributions — with pathogenesis involving UV-induced melanocyte stimulation, hormonal influences (oestrogen, progesterone), and visible light sensitivity. Vitiligo is an autoimmune disorder in which cytotoxic T-lymphocyte-mediated destruction of melanocytes produces depigmented, chalk-white macules and patches with sharp borders; it affects 0.5-2% of the global population and can cause significant psychological distress, particularly in patients with darker skin phototypes where the contrast is most striking. Each condition requires a tailored treatment strategy based on pathogenesis, distribution, Fitzpatrick skin phototype, and patient goals. A shared principle across all pigmentation disorders is that strict year-round sun protection with broad-spectrum SPF 50+ sunscreen is an absolute prerequisite for any treatment to be effective and for preventing recurrence.

Treatment is indicated for patients with cosmetically distressing pigmentation causing psychological impact, or for progressive conditions where early intervention prevents worsening. Melasma patients unresponsive to photoprotection and first-line topical bleaching agents, and those with psychosocial impact, benefit most from combined therapy. Vitiligo patients with rapidly progressive, widespread (over 10% body surface), or psychologically distressing disease, particularly facial involvement, are candidates for systemic or procedural treatments. Solar lentigines and freckles responsive to laser therapy are suitable for patients with stable lesions. Darker skin phototypes (Fitzpatrick IV-VI) carry higher risk of post-inflammatory hyperpigmentation from laser and chemical peel procedures and require expert assessment and appropriate technique modification before treatment. Vitiligo patients with rapidly progressive disease affecting over 10% body surface area, or segmental vitiligo where lesions are confined to one dermatome and have been stable for at least 6 months, represent distinct clinical subtypes requiring different management approaches. All patients benefit from psychological support and connection with peer support networks.

Hyperpigmentation (freckles, lentigines, melasma): first-line treatment combines daily broad-spectrum SPF 50+ sunscreen — the single most important intervention — with topical depigmenting agents applied to affected areas. Hydroquinone 2-4% (tyrosinase inhibitor), azelaic acid 15-20%, kojic acid, tranexamic acid, arbutin, and niacinamide are used individually or in combination formulations; the triple combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone acetonide 0.01%) is the gold-standard prescription therapy for melasma. Topical agents are applied once or twice daily to affected areas only, with care to avoid surrounding normal skin. For persistent pigmentation, procedural interventions are added: chemical peels using glycolic acid 30-70%, salicylic acid 20-30%, or mandelic acid are applied by dermatologists in series of 4-6 sessions every 2-4 weeks. Q-switched or picosecond Nd:YAG laser, Q-switched ruby laser, and intense pulsed light (IPL) are used for lentigines and freckles unresponsive to topical treatment. Vitiligo treatment: first-line is topical calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus 1%) or potent topical corticosteroids applied to lesions twice daily for 3 months. Narrowband UVB (NB-UVB) phototherapy at 311 nm is the most effective treatment for widespread or stable vitiligo; administered 2-3 sessions per week for 6-12 months. Excimer laser (308 nm) is targeted for localised lesions. Surgical melanocyte transplantation (suction blister grafting, split skin grafting, or autologous non-cultured melanocyte-keratinocyte transplantation) is offered for stable segmental vitiligo unresponsive to medical therapy.

Q-switched Nd:YAG laser achieves greater than 75% clearance of solar lentigines and ephelides in 1-2 treatment sessions. The triple combination cream for melasma reduces melanin index by 40-60% over 8 weeks compared to hydroquinone monotherapy. Narrowband UVB phototherapy achieves meaningful repigmentation — defined as greater than 50% repigmentation of lesions — in 50-70% of vitiligo patients after 6-12 months of regular treatment; the face, neck, and proximal limbs respond best, while acral sites (fingertips, lips) respond poorly. New JAK inhibitor therapy — oral ruxolitinib and topical ruxolitinib 1.5% cream — has demonstrated significant repigmentation in vitiligo, with the topical formulation receiving FDA approval in 2022, showing 30-75% repigmentation at 24 weeks in randomised trials. Surgical melanocyte transplantation for stable segmental vitiligo achieves greater than 80% repigmentation in carefully selected patients. Strict photoprotection with SPF 50+ sunscreen throughout and beyond treatment is the single most impactful intervention for maintaining all achieved pigmentation improvements and preventing recurrence.

Laser treatments risk post-inflammatory hyperpigmentation (PIH) in darker skin phototypes (Fitzpatrick IV-VI), as melanocyte damage triggers increased pigmentation — appropriate wavelength selection, test patches, and shorter pulse durations reduce this risk. Hydroquinone causes exogenous ochronosis (paradoxical grey-blue skin darkening) with prolonged use beyond 6 months in some patients, particularly in darker skin types. Chemical peels risk uneven pigmentation, scarring, and bacterial or viral (HSV) infection; antiviral prophylaxis (aciclovir) is prescribed for patients with a history of cold sores. Topical corticosteroids in triple combination creams cause skin atrophy, telangiectasia, and perioral dermatitis with prolonged or unsupervised use. Narrowband UVB increases cumulative UV exposure and long-term skin cancer risk, requiring melanoma surveillance. Ruxolitinib cream carries a theoretical JAK inhibitor class label warning for malignancy and thromboembolism based on systemic JAK inhibitor data.

Topical treatments require 8-12 weeks for initial response and 3-6 months of consistent use for maximum benefit; strict daily SPF 50+ broad-spectrum sunscreen is mandatory throughout and beyond treatment, as UV exposure negates all pigmentation therapy. After laser procedures, treated skin is red and oedematous for 24-48 hours, with purpura or crusting for 5-14 days depending on wavelength and technique; patients are advised to apply petroleum jelly, avoid sun, and use gentle cleansers during healing. NB-UVB phototherapy sessions increase in dose over months; patients attend 2-3 times weekly for 1-2 years in hospital phototherapy units. Vitiligo repigmentation may be maintained with monthly NB-UVB or twice-daily topical ruxolitinib after active treatment. Cosmetic camouflage (medical-grade self-tanning products, microblading for facial vitiligo) provides interim cosmetic benefit throughout treatment.